Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Cars.com
CARS
5
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
US OptionsDetailed Quotes
APLS250417P43000
- 10.20
- 0.000.00%
15min DelayClose Apr 4 16:00 ET
0.00High0.00Low
10.20Open10.20Pre Close0 Volume8 Open Interest43.00Strike Price0.00Turnover196.05%IV-64.25%PremiumApr 17, 2025Expiry Date23.03Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9826Delta0.0086Gamma0.87Leverage Ratio-0.0094Theta-0.0050Rho-0.85Eff Leverage0.0015Vega
Apellis Pharmaceuticals Newsroom
RBC Capital Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $24
Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $31
Apellis Pharmaceuticals Analyst Ratings
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Raises Target Price to $31
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?
Apellis Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Acceptance, Priority Review of SNDA for EMPAVELI.
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
Express News | Apellis Pharmaceuticals Inc - Pdufa Target Action Date for Empaveli Is July 28, 2025
Express News | Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli® (Pegcetacoplan) for C3G and Primary Ic-Mpgn
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI (Pegcetacoplan) for C3G and Primary IC-MPGN
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts
Evercore ISI Remains a Buy on Apellis Pharmaceuticals (APLS)
Morgan Stanley Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Cautious Hold on Apellis Pharmaceuticals Amid Competitive Landscape and Promising Empaveli Prospects
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $57
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
William Blair Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call